Brolucizumab-dbll

Brolucizumab-dbll Uses, Dosage, Side Effects, Food Interaction and all others data.

Brolucizumab-dbll, also known as RTH258 or ESBA1008, is a monoclonal antibody indicated to treat neovascular age related macular degeneration.

Brolucizumab-dbll was granted FDA approval in October 2019.

Brolucizumab-dbll is a vascular endothelial growth factor (VEGF) inhibitor which reduces proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature. It has a long duration of action as it is given monthly. Patients should be counselled regarding the risk of endophthalmitis, retinal detachment, and arterial thromboembolic events following administration of this medication.

Brolucizumab-dbll
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Brolucizumab-dbll
Availability	Prescription only
Generic	Brolucizumab
Brolucizumab Other Names	Brolucizumab, brolucizumab-dbll
Related Drugs	Avastin, Eylea, Lucentis, Beovu, dexamethasone ophthalmic, Vabysmo, fluocinolone ophthalmic, aflibercept ophthalmic, ranibizumab ophthalmic
Type	Intraocular
Weight	26000.0 Da (approximate)
Protein binding	Monoclonal antibodies are generally not protein bound in serum.
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	United States
Last Updated:	September 19, 2023 at 7:00 am

Uses

Brolucizumab-dbll is an anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration.

Brolucizumab-dbll is a monoclonal antibody indicated to treat neovascular age related macular degeneration.

Brolucizumab-dbll is also used to associated treatment for these conditions: Neovascular Age Related Macular Degeneration

How Brolucizumab-dbll works

Brolucizumab-dbll is a vascular endothelial growth factor (VEGF) inhibitor which targets the major VEGF-A isoforms: VEGF₁₁₀, VEGF₁₂₁, and VEGF₁₆₅. Inhibition of these VEGF-A isoforms reduce proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature.

Toxicity

Data regarding the toxicity of brolucizumab is not readily available.

Food Interaction

No interactions found.

Volume of Distribution

Data regarding the volume of distribution is not readily available.

Elimination Route

A 3mg dose of brolucizumab reaches a C_max of 20.7ng/mL with a T_max of 20.3h and an AUC of 2480ng*h/mL. A 6mg dose of brolucizumab reaches a C_max of 77.6ng/mL with a T_max of 17.4h and an AUC of 9169ng*h/mL.

Half Life

The systemic half life of bolucizumab is 4.4±2.0 days. The elimination half life is 108h for a 3mg dose and 103h for a 6mg dose.

Clearance

Data regarding the clearance of brolucizumab is not readily available.

Elimination Route

Data regarding the route of elimination is not readily available. Monoclonal antibodies are generally not eliminated in the urine, and only a small amount is excreted in bile.